TriangleNCT01536145 · OUTCOME
Single Dose Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for CP-751,871
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEAN
- Unit
- milligram•hour/liter (mg•hr/L)
- Interval / dispersion
- Standard Deviation
- Time frame
- Cycle 1: predose; 1; 24; 48; 72; 168; 336; 504, 672 and 1008 (for participants with an up to 8-week Cycle 1 only) hours postdose
Analysis population: All participants treated who had at least 1 of the pharmacokinetic (PK) parameters of primary interest.
Groups in this outcome
CP-751,871 0.1 mg/kg
CP-751,871 0.1 mg/kg administered intravenously on Day 1 of Cycle 1 (4 weeks or 8 weeks), and dose of 50% from the Cycle 1 dose administered on Day 1 of subsequent cycles, starting from Cycle 2 (4 weeks)
CP-751,871 0.2 mg/kg
CP-751,871 0.2 mg/kg administered intravenously on Day 1 of Cycle 1 (4 weeks or 8 weeks), and dose of 50% from the Cycle 1 dose administered on Day 1 of subsequent cycles, starting from Cycle 2 (4 weeks)
CP-751,871 0.4 mg/kg
CP-751,871 0.4 mg/kg administered intravenously on Day 1 of Cycle 1 (4 weeks or 8 weeks), and dose of 50% from the Cycle 1 dose administered on Day 1 of subsequent cycles, starting from Cycle 2 (4 weeks)
CP-751,871 0.8 mg/kg
CP-751,871 0.8 mg/kg administered intravenously on Day 1 of Cycle 1 (4 weeks or 8 weeks), and dose of 50% from the Cycle 1 dose administered on Day 1 of subsequent cycles, starting from Cycle 2 (4 weeks)
CP-751,871 1.5 mg/kg
CP-751,871 1.5 mg/kg administered intravenously on Day 1 of Cycle 1 (4 weeks or 8 weeks), and dose of 50% from the Cycle 1 dose administered on Day 1 of subsequent cycles, starting from Cycle 2 (4 weeks)
CP-751,871 3 mg/kg
CP-751,871 3 mg/kg administered intravenously on Day 1 of Cycle 1 (4 weeks or 8 weeks), and dose of 50% from the Cycle 1 dose administered on Day 1 of subsequent Cycles, starting from Cycle 2 (4 weeks)
CP-751,871 6 mg/kg
CP-751,871 6 mg/kg administered intravenously on Day 1 of Cycle 1 (4 weeks or 8 weeks), and dose of 50% from the Cycle 1 dose administered on Day 1 of subsequent cycles, starting from Cycle 2 (4 weeks)
CP-751,871 10 mg/kg
CP-751,871 10 mg/kg administered intravenously on Day 1 of Cycle 1 (4 weeks or 8 weeks) and subsequent cycles, starting from Cycle 2 (4 weeks)
CP-751,871 20 mg/kg
CP-751,871 20 mg/kg administered intravenously on Day 1 of Cycle 1 (4 weeks or 8 weeks) and subsequent cycles, starting from Cycle 2 (4 weeks)
| Group | Source count |
|---|---|
| CP-751,871 0.1 mg/kg | 2 |
| CP-751,871 0.2 mg/kg | 3 |
| CP-751,871 0.4 mg/kg | 4 |
| CP-751,871 0.8 mg/kg | 3 |
| CP-751,871 1.5 mg/kg | 3 |
| CP-751,871 3 mg/kg | 4 |
| CP-751,871 6 mg/kg | 3 |
| CP-751,871 10 mg/kg | 7 |
| CP-751,871 20 mg/kg | 6 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| CP-751,871 0.1 mg/kg | 101 | NA | Not reported | Not reported | Number of participants analyzed was less than 3, thus standard deviation was not calculated. |
| CP-751,871 0.2 mg/kg | 202 | 29.2 | Not reported | Not reported | Not reported |
| CP-751,871 0.4 mg/kg | 1016 | 583 | Not reported | Not reported | Not reported |
| CP-751,871 0.8 mg/kg | 2079 | 1413 | Not reported | Not reported | Not reported |
| CP-751,871 1.5 mg/kg | 8380 | 4533 | Not reported | Not reported | Not reported |
| CP-751,871 3 mg/kg | 15436 | 6406 | Not reported | Not reported | Not reported |
| CP-751,871 6 mg/kg | 26144 | 2672 | Not reported | Not reported | Not reported |
| CP-751,871 10 mg/kg | 38700 | 15019 | Not reported | Not reported | Not reported |
| CP-751,871 20 mg/kg | 95565 | 25891 | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- comment
- Number of participants analyzed was less than 3, thus standard deviation was not calculated.
- group Id
- OG000
- spread
- NA
- value
- 101
- group Id
- OG001
- spread
- 29.2
- value
- 202
- group Id
- OG002
- spread
- 583
- value
- 1016
- group Id
- OG003
- spread
- 1413
- value
- 2079
- group Id
- OG004
- spread
- 4533
- value
- 8380
- group Id
- OG005
- spread
- 6406
- value
- 15436
- group Id
- OG006
- spread
- 2672
- value
- 26144
- group Id
- OG007
- spread
- 15019
- value
- 38700
- group Id
- OG008
- spread
- 25891
- value
- 95565
- denoms
- counts
- group Id
- OG000
- value
- 2
- group Id
- OG001
- value
- 3
- group Id
- OG002
- value
- 4
- group Id
- OG003
- value
- 3
- group Id
- OG004
- value
- 3
- group Id
- OG005
- value
- 4
- group Id
- OG006
- value
- 3
- group Id
- OG007
- value
- 7
- group Id
- OG008
- value
- 6
- units
- Participants
- dispersion Type
- Standard Deviation
- groups
- description
- CP-751,871 0.1 mg/kg administered intravenously on Day 1 of Cycle 1 (4 weeks or 8 weeks), and dose of 50% from the Cycle 1 dose administered on Day 1 of subsequent cycles, starting from Cycle 2 (4 weeks)
- id
- OG000
- title
- CP-751,871 0.1 mg/kg
- description
- CP-751,871 0.2 mg/kg administered intravenously on Day 1 of Cycle 1 (4 weeks or 8 weeks), and dose of 50% from the Cycle 1 dose administered on Day 1 of subsequent cycles, starting from Cycle 2 (4 weeks)
- id
- OG001
- title
- CP-751,871 0.2 mg/kg
- description
- CP-751,871 0.4 mg/kg administered intravenously on Day 1 of Cycle 1 (4 weeks or 8 weeks), and dose of 50% from the Cycle 1 dose administered on Day 1 of subsequent cycles, starting from Cycle 2 (4 weeks)
- id
- OG002
- title
- CP-751,871 0.4 mg/kg
- description
- CP-751,871 0.8 mg/kg administered intravenously on Day 1 of Cycle 1 (4 weeks or 8 weeks), and dose of 50% from the Cycle 1 dose administered on Day 1 of subsequent cycles, starting from Cycle 2 (4 weeks)
- id
- OG003
- title
- CP-751,871 0.8 mg/kg
- description
- CP-751,871 1.5 mg/kg administered intravenously on Day 1 of Cycle 1 (4 weeks or 8 weeks), and dose of 50% from the Cycle 1 dose administered on Day 1 of subsequent cycles, starting from Cycle 2 (4 weeks)
- id
- OG004
- title
- CP-751,871 1.5 mg/kg
- description
- CP-751,871 3 mg/kg administered intravenously on Day 1 of Cycle 1 (4 weeks or 8 weeks), and dose of 50% from the Cycle 1 dose administered on Day 1 of subsequent Cycles, starting from Cycle 2 (4 weeks)
- id
- OG005
- title
- CP-751,871 3 mg/kg
- description
- CP-751,871 6 mg/kg administered intravenously on Day 1 of Cycle 1 (4 weeks or 8 weeks), and dose of 50% from the Cycle 1 dose administered on Day 1 of subsequent cycles, starting from Cycle 2 (4 weeks)
- id
- OG006
- title
- CP-751,871 6 mg/kg
- description
- CP-751,871 10 mg/kg administered intravenously on Day 1 of Cycle 1 (4 weeks or 8 weeks) and subsequent cycles, starting from Cycle 2 (4 weeks)
- id
- OG007
- title
- CP-751,871 10 mg/kg
- description
- CP-751,871 20 mg/kg administered intravenously on Day 1 of Cycle 1 (4 weeks or 8 weeks) and subsequent cycles, starting from Cycle 2 (4 weeks)
- id
- OG008
- title
- CP-751,871 20 mg/kg
- param Type
- MEAN
- population Description
- All participants treated who had at least 1 of the pharmacokinetic (PK) parameters of primary interest.
- reporting Status
- POSTED
- time Frame
- Cycle 1: predose; 1; 24; 48; 72; 168; 336; 504, 672 and 1008 (for participants with an up to 8-week Cycle 1 only) hours postdose
- title
- Single Dose Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for CP-751,871
- type
- SECONDARY
- unit Of Measure
- milligram•hour/liter (mg•hr/L)
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice